Skip to main content

Table 1 Baseline characteristics

From: Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study

  OAT-Biomarker (N = 70) Remaining OAT (N = 2131)  
  n % (mean ± sd) N % (mean ± sd) p-value
Age (years) 70 (60.8 ± 8.8) 2131 (58.5 ± 11) 0.097
Women 17 24.3 467 21.9 0.637
Race White 70 100 1693 79.4 <.001
Clinical history      
  Angina 15 21.4 480 22.5 0.829
  Myocardial Infarction 3 4.3 244 11.5 0.080
  Percutaneous intervention 4 5.7 101 4.7 0.574
  Congestive heart failure 1 1.4 51 2.4 1.000
  Hypertension 36 51.4 1035 48.6 0.638
  Diabetes 10 14.3 444 20.8 0.183
  Insulin use 6 8.6 118 5.5 0.279
  Hypercholesterolemia 31 44.3 1111 52.2 0.195
  Stroke 4 5.7 59 2.8 0.138
  Cerebrovascular disease 5 7.1 77 3.6 0.125
  Peripheral vascular disease 1 1.4 82 3.9 0.519
  Current Smoker 25 35.7 834 39.1 0.564
  Family history CAD 29 41.4 854 40.1 0.820
Days from MI to randomization - median {IQR} 70 21{16–26} 2131 8{5–16} <.001
Index myocardial infarction      
  Received thrombolytics 1 1.4 423 19.9 <.001
  STE / Q wave / R loss 58 82.9 1849 86.8 0.344
  Killip Class II-IV 11 15.7 406 19.1 0.473
  Ejection Fraction 70 (46.3 ± 9.7) 2115 (47.8 ± 11.1) 0.275
  Rales 1 1.4 136 6.4 0.125
Clinical measures      
  Estimated GFR <60 ml/min/1.73 m2 8 11.4 305 14.6 0.453
  Glucose > =126 mg/dl 8 11.6 556 28.8 0.002
  BMI (kg/m2) 69 (26.7 ± 3.6) 2118 (28.6 ± 5.1) 0.003
  Heart rate (bpm) 70 (69.3 ± 9.8) 2128 (71.9 ± 12) 0.076
  Systolic blood pressure (mmHg) 70 (120.4 ± 11.9) 2129 (120.8 ± 18.1) 0.831
Angiography      
  Infarct-related artery (IRA) –LAD 19 27.1 774 36.3 . 0.267
  Infarct-related artery (IRA) –Lcx 11 15.7 324 15.2
  Infarct-related artery (IRA) –RCA 40 57.1 1033 48.5
  Multivessel Disease 21 30.4 358 16.9 0.004
  Collaterals 64 92.8 1858 88.3 0.256
Medications      
  Aspirin 68 97.1 2037 95.6 0.767
  Thienopyridine 42 60 1287 60.4 0.947
  Warfarin 3 4.3 212 9.9 0.150
  Beta blocker 65 92.9 1867 87.6 0.187
  Calcium blocker 2 2.9 127 6 0.434
  Lipid lowering agent 68 97.1 1720 80.7 <.001
  Spironolactone 9 12.9 115 5.4 0.008
  ACE-Inhibitor or ARB 62 88.6 1709 80.2 0.082
  1. ACE-angiotensin converting enzyme, ARB-angiotensin receptor blocker, BMI-body mass index, BP, blood pressure, CAD-coronary artery disease, GFR-glomerular filtration rate, IQR-interquartile ranges, IRA-infarct related artery, LAD-left anterior descending artery, LCX-left circumflex coronary artery, RCA-right coronary artery, STE-ST elevation.